{"data":{"id":"us-ok/okla.-stat.-tit.-63-63-5030.3","jurisdiction":"us-ok","citation":"Okla. Stat. tit. 63, § 63-5030.3","heading":"Powers and duties of board","body":"\n\nA. The Medicaid Drug Utilization Review Board shall have the\n\npower and duty to:\n\n1. Advise and make recommendations regarding rules promulgated\n\nby the Oklahoma Health Care Authority Board to implement the\n\nprovisions of this act;\n\n2. Oversee the development, implementation and assessment of a\n\nMedicaid retrospective and prospective drug utilization review\n\nprogram, including making recommendations regarding contractual\n\nagreements of the Oklahoma Health Care Authority with any entity\n\ninvolved in processing and reviewing Medicaid drug profiles for the\n\ndrug utilization review program in accordance with the provisions of\n\nthis act;\n\n3. Develop and apply the criteria and standards to be used in\n\nretrospective and prospective drug utilization review. The criteria\n\nand standards shall be based on the compendia and federal Food and\n\nDrug Act approved labeling, and shall be developed with professional\n\ninput;\n\n4. Provide a period for public comment on each meeting agenda.\n\nAs necessary, the Medicaid Drug Utilization Review Board may include\n\na public hearing as part of a meeting agenda to solicit public\n\ncomment regarding proposed changes in the prior authorization\n\nprogram and the retrospective and prospective drug utilization\n\nreview processes. Notice of proposed changes to the prior\n\nauthorization status of a drug or drugs shall be included in the\n\nmonthly meeting agenda at least thirty (30) days prior to the\n\nconsideration or recommendation of any proposed changes in prior\n\nauthorization by the Medicaid Drug Utilization Review Board;\n\n5. Establish provisions to timely reassess and, as necessary,\n\nrevise the retrospective and prospective drug utilization review\n\nprocess;\n\n6. Make recommendations regarding the prior authorization of\n\nprescription drugs pursuant to the provisions of Section 5 of this\n\nact; and\n\n7. Provide members of the provider community with educational\n\nopportunities related to the clinical appropriateness of\n\nprescription drugs.\n\nB. Any party aggrieved by a decision of the Oklahoma Health\n\nCare Authority Board or the Administrator of the Oklahoma Health\n\nCare Authority, pursuant to a recommendation of the Medicaid Drug\n\nUtilization Review Board, shall be entitled to an administrative\n\nhearing before the Oklahoma Health Care Authority Board pursuant to\n\nthe provisions of the Administrative Procedures Act.","path":["OK Code","Title 63"],"source_url":"https://www.oklegislature.gov/OK_Statutes/CompleteTitles/os63.pdf","current_through":"2026-08-14","vintage":"open-us-law v2026.08, retrieved 2026-09-14","retrieved_at":"2026-09-14T18:32:36Z","sha256":"847519aa70498903ee609279a2a370f1694354df8e4e797ded039b20fe0f08f7","source_id":"us-ok","stale":false,"prev":"us-ok/okla.-stat.-tit.-63-63-5030.2","next":"us-ok/okla.-stat.-tit.-63-63-5030.4"},"notice":"GroundRules: Original legal text. Not legal advice."}